Fig. 1. (A)
Solitary dark-colored plaque on the patient's right cheek with foul-smelling discharge on squeezing. (B) Histopathological findings in the excised specimen showed congenital melanocytic nevus with multiple cysts filled with keratinous material (H&E, ×10), and melanocytic nevus cells were imbedded along the epithelium of a huge epidermal cyst resembling buddings on the tree (inset, ×100). Here, we present an interesting case of CMN with distinctive nevus cell proliferation within multiple epidermal cyst-like changes.
A 57-year-old man presented for evaluation of a lesion on his face, which he had had since birth. He reported that the lesion had gradually become darker and larger, and complained about foul-smelling cheese-like discharge upon squeezing. Physical examination revealed a solitary 1.2×2.0-cm dark-colored plaque on his right cheek. The lesion had a large dilated pore in the center and multiple adjacent small pits on its surface. The nevus was excised, and a rotational flap was used to cover the defect. Histopathological examination of the excised lesion revealed diffuse infiltration of melanocytes in the reticular dermis, hair follicles, and sebaceous glands, showing typical features of CMN along with multiple cysts filled with keratinous material (Fig. 1A) . Unlike other CMN-containing epidermal cysts, melanocytic nevus cells were imbedded along the epithelium of a huge epidermal cyst, resembling buddings from a tree (Fig. 1B) . At the 4-month follow-up, the patient had a well-healed scar and no evidence of recurrence.
There are multiple cases of nevus with cysts in the liter- cells imbedded in the wall of a cyst as seen in the present case. Thus, here, we report a rare case of CMN with distinctive nevus cell proliferation within multiple epidermal cyst-like changes. We suspect that this happened through migration of nevus cells into the epithelium during the formation of connections between the cyst wall and epidermis, or by direct invasion of the epithelium of the epidermal cyst. Dear Editor: Chronic pruritus is difficult to treat and severely affects patient's quality of life and psychological well-being. Substance P (SP) is an important mediator in the induction and maintenance of pruritus, and therefore represents a promising target for antipruritic treatment. Aprepitant is an oral neurokinin-1 receptor (NK-1R) antagonist, which acts by inhibiting the binding of the NK-1R with the SP ligand in the skin and central nervous system 1, 2 .
Treatment for Refractory Pruritus Using Oral Aprepitant
A 79-year-old man presented with refractory pruritus that had been resistant to local application of corticosteroid, standard systemic therapies such as antihistamine, cyclosporine, gabapentin and tricyclic antidepressant, and phototherapy. The origin of pruritus was unclear despite extensive laboratory and radiological investigation. Histopathological examination of a biopsy taken from the lower back showed superficial psoriasiform dermatitis with spongiosis and parakeratosis. He complained that he could not sleep for more than 1 hour because of the pruritus. After stopping antipruritic treatment for 3 weeks, we administered 125 mg of aprepitant on day 1 and 80 mg on day 2, 3 and 4 at the same time of day. Before treatment, visual analogue scale (VAS) score was 8/10 and Dermatologic Life Quality Index (DLQI) score was 24/30. After 24 hours from first administration, these values reduced to 4 and 16, respectively. He mentioned that pruritus was reduced significantly and he could consistently sleep for more than 4 hours. After 6 weeks, VAS and DLQI scores were 1 and 8 (Table 1) , and his cutaneous lesions were much improved (Fig. 1) . He was completely satisfied
